Abstract 386P
Background
Searching for specific targets in cancer diagnosis and treatment is one of the most important problems in clinical oncology. We put forward a new concept of the emergence of tumor-specific epitopes of integral membrane proteins by changing their topology under mutations, glycosylation and tumor conditions including low pH and hypoxia on the model of Na-dependent phosphate-cotransporter NaPi2b. NaPi2b (SLC34A2, NaPi-IIb, NPT2b) belongs to the SLC34A2 transporters family and is involved in maintaining phosphate homeostasis in the human body. NaPi2b express in a number of normal and malignant tissues, including ovarian, breast and triple-negative breast cancer. It is an integral membrane protein with a large extramembrane domain 4 (EMD4, 234-362 aa), 8 transmembrane domains, N - and C - ends located in the cytoplasm.
Methods
We have cloned the epitope for antibodies MX35 and L2 (20/3) within 311-340 aa region of NaPi2b, which recognition depends on disulfide bonds, glycosylation and is canceled by the mutation at the T330V position. Topology of the protein undergoing significant changes in hypoxia and low pH conditions.
Results
N-terminal domain of NaPi2b can be localized outside the cells during hypoxia and low pH and return to its primary topology at the inner leaflet membrane in normoxia conditions. This reorientation makes it as a potential tumor-specific domain.
Conclusions
The obtained data are of both fundamental and applied importance in the development of new targeted antitumor drugs of high specificity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kazan Federal University.
Funding
Russian Government Program of Competitive Growth of KFU.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
465P - A phase IIIb open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: Exploratory biomarker analysis
Presenter: Jie Wang
Session: Poster display session
Resources:
Abstract
470P - Prognostic significance of serum biomarkers in small cell lung cancer: A meta-analysis and systematic review
Presenter: Rogelio Velasco
Session: Poster display session
Resources:
Abstract
471P - Chemotherapy in advanced thymic malignancies
Presenter: Ankur Varshney
Session: Poster display session
Resources:
Abstract
466P - Cancer immunotherapy efficacy and patients’ age: A systematic review and meta-analysis
Presenter: Yu Jiang
Session: Poster display session
Resources:
Abstract
506P - Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC)
Presenter: Jeffrey Ward
Session: Poster display session
Resources:
Abstract
480P - Safety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050
Presenter: Tony S.K. Mok
Session: Poster display session
Resources:
Abstract
503P - Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials
Presenter: Antonio Passaro
Session: Poster display session
Resources:
Abstract
488P - Randomized trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancer (PEARL trial)
Presenter: Kei Kusaka
Session: Poster display session
Resources:
Abstract
495P - Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
Presenter: Anna Buder
Session: Poster display session
Resources:
Abstract
520P - A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)
Presenter: Akito Hata
Session: Poster display session
Resources:
Abstract